BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS

Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023

BIO-PATH HOLDINGS REPORTS FULL YEAR 2022 FINANCIAL RESULTS

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023

Bio-Path Holdings Provides Clinical and Operational Update

Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS

Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022

Bio-Path Holdings Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement

Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference

BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022

BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS

Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022

Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting

Bio-Path Holdings Appoints Aline Sherwood to Board of Directors

Bio-Path Holdings Reports Full Year 2021 Financial Results

Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting

Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022

Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting

Bio-Path Holdings Reports Third Quarter 2021 Financial Results

Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021

Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path Holdings Reports Second Quarter 2021 Financial Results

Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021

Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003

Bio-Path Holdings Reports First Quarter 2021 Financial Results

Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021

Bio-Path Announces Publication in Biomedicines

Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting

Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting

BIO-PATH HOLDINGS REPORTS FULL YEAR 2020 FINANCIAL RESULTS

Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021

Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock

Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock

Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology

Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS

Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020

Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers

Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS

Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia

Bio-Path Holdings to Announce Second Quarter 2020 Financial Results on August 14, 2020

Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting

BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual Meeting

Bio-Path Holdings to Announce First Quarter 2020 Financial Results on May 15, 2020

Bio-Path Holdings Presents at 2020 American Association for Cancer Research Annual Meeting

Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting

Bio-Path Holdings Appoints Ernst & Young as New Auditor

BIO-PATH HOLDINGS REPORTS FULL YEAR 2019 FINANCIAL RESULTS

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2019 Financial Results on March 6, 2020

Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook

BIO-PATH HOLDINGS ANNOUNCES SUCCESSFUL COMPLETION OF SAFETY TESTING IN STAGE 2 OF PHASE 2 CLINICAL TRIAL IN ACUTE MYELOID LEUKEMIA

Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market

BIO-PATH HOLDINGS ANNOUNCES CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR BP1002

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS

Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019

Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors

Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent

Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Acute Myeloid Leukemia Trial

BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS

Bio-Path Holdings to Announce Second Quarter 2019 Financial Results on August 15, 2019

BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS

Bio-Path Holdings to Announce First Quarter 2019 Financial Results on May 16, 2019

Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019 — Highlighting Important Cancer Gene, STAT3, Therapeutic Strategy in Pancreatic, Non-Small Cell Lung Cancers and Acute Myelogenous Leukemia

BIO-PATH HOLDINGS REPORTS FULL YEAR 2018 FINANCIAL RESULTS: Conference Call to be Held Today at 8:30 a.m. ET

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019

Bio-Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common Stock

Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock

Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting

Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market

Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock

Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock (Pricing)

Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock (Launch)

Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook

Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS

Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018

Bio-Path Holdings to Present Clinical Data at the 60th Annual American Society of Hematology Annual Meeting

Bio-Path Holdings, Inc. Announces Closing of $1.5 Million Registered Direct Offering

Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering

Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference

Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia

Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board

BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS

Bio-Path Holdings to Announce Second Quarter 2018 Financial Results on August 15, 2018

BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board

Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018

Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting

Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine (LDAC) for the Treatment of Acute Myeloid Leukemia (AML)

BIO-PATH HOLDINGS REPORTS FULL YEAR 2017 FINANCIAL RESULT

Bio-Path Holdings Announces Publication in The Lancet Haematology

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2017 Financial Results on April 3, 2018

Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting

Bio-Path Holdings to Present at the 30th Annual ROTH Conference

Bio-Path Holdings Announces 1-for-10 Reverse Stock Split

Bio-Path Holdings to Present at the BIO CEO & Investor Conference

Bio-Path Holdings Appoints Paul Aubert to its Board of Directors

Bio-Path Holdings Provides Clinical Update and 2018 Business Outlook

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS

Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts

Bio-Path Holdings, Inc. Announces $4 Million Registered Direct Offering

Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017

Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference

BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS

Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017

Bio-Path Holdings Receives Notice of Allowance for Key U.S. Composition of Matter Patent

Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors

Stockholder Letter

BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS

Bio-Path Holdings to Announce First Quarter 2017 Financial Results on May 11, 2017

Bio-Path Holdings Announces Appointment of Dr. William Hahne as Vice President of Clinical Development

Bio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkin’s Lymphoma

BIO-PATH HOLDINGS REPORTS FULL YEAR 2016 FINANCIAL RESULTS

Bio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare Conference

Bio-Path Holdings Announces Rescheduled Date and Time of Full Year 2016 Financial Results on March 15, 2017

Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017

Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board

Bio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference

Bio-Path Holdings Presents Clinical Data Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia at the 58th Annual American Society of Hematology Annual Meeting

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS

BIO-PATH HOLDINGS TO ANNOUNCE THIRD QUARTER 2016 FINANCIAL RESULTS ON NOVEMBER 10, 2016

Bio-Path Holdings to Present Data at the 2016 ASH Annual Meeting

Bio-Path Announces Orphan Drug Designation in the European Union for BP1001 for the Treatment of Acute Myeloid Leukemia

Bio-Path Holdings Announces First Patient Dosed in Phase 2 Trial Evaluating BP1001 in Acute Myeloid Leukemia

Bio-Path Holdings to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS

BIO-PATH HOLDINGS TO ANNOUNCE SECOND QUARTER 2016 FINANCIAL RESULTS ON AUGUST 10, 2016

Bio-Path Holdings to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference

Bio-Path Holdings, Inc. Announces $10 Million Registered Direct Offering

Bio-Path Holdings Announces Collaboration With Thomas Jefferson University for Systemic Antisense Immunotherapy Treatment for Brain Cancer

Bio-Path Holdings to Join Russell 3000® and Global Indexes

Bio -Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016

Bio-Path Holdings to Present Data at 2016 American Society of Clinical Oncology Annual Meeting

Bio-Path Holdings Reports First Quarter 2016 Financial Results

Bio-Path Holdings to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutic Conference

Bio-Path Holdings to Announce First Quarter 2016 Financial Results on May 11, 2016

Bio-Path Holdings Announces Research Collaboration on Autoimmune Indication with The University of Texas Southwestern Medical Center

Bio-Path Holdings Reports Fiscal Year 2015 Operational and Financial Results

Bio-Path Holdings Announces Pancreatic Cancer Research Collaboration with Leading Oncology Institution

Bio-Path Holdings to Present at the 28th Annual ROTH Conference on Monday, March 14 at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time)

Bio-Path Holdings Announces Completion of the Safety Segment of the Phase II Clinical Trial of BP1001 in Acute Myeloid Leukemia

Bio-Path Holdings to Present at Biotech Showcase™ 2016

Bio-Path Holdings’ Data from Phase I and Safety Segment of Phase II Clinical Trials in Blood Cancers Presented at 57th American Society of Hematology (ASH) Annual Meeting

Bio-Path Holdings Reports Third Quarter 2015 Operational and Financial Results

Bio-Path Holdings’ Data to be Presented at 57th American Society of Hematology (ASH) Annual Meeting

Bio-Path Holdings to Present at the 14th Annual BIO Investor Forum

Bio-Path Holdings Announces Successful Completion of Cohort 7 of Phase Ib of Clinical Trial Evaluating Liposomal Grb-2 in Acute Myeloid Leukemia

Bio-Path Holdings To Present at the 17th Annual Rodman & Renshaw Global Investment Conference

Bio-Path Holdings Forms Scientific Advisory Board to Support Advancement of Liposomal Grb-2 in Blood Cancers

Bio-Path Holdings Reports Second Quarter 2015 Operational and Financial Results

Bio-Path Holdings Announces “At the Market” Offering with Cantor Fitzgerald

Bio-Path Holdings Reports First Quarter 2015 Operational and Financial Results

Bio-Path Holdings Granted Orphan Drug Designation for Liposomal Grb-2 in Acute Myeloid Leukemia

Letter to Shareholder from President and CEO

Bio-Path Holdings’ Drug Delivery Technology to be Featured in a Presentation at IBC’s 17th Annual TIDES Oligoneucleotide and Peptide Therapeutics Conference

Bio-Path Holdings Reports Fiscal Year 2014 Operational and Financial Results

Letter to Shareholder from President and CEO

Bio-Path Holdings Starts Phase II Study with Liposomal Grb-2 in AML Patients

Bio-Path Holdings’ Liposomal Grb-2 Featured in Peer-Reviewed Journal “Expert Opinion on Drug Delivery”

Bio-Path Holdings to Present at the Biotech Showcase 2015 Conference in San Francisco, CA on Tuesday, January 13, 2015 at 3:30 p.m. Pacific Time

Bio-Path Holdings to Initiate Development of Liposomal Bcl-2 in Follicular Lymphoma – Company Broadening its Pipeline with Second Product Candidate –

Bio-Path Holdings Reports Third Quarter 2014 Operational and Financial Results

Bio-Path Holdings Appoints Amy P. Sing, M.D. to its Board of Directors

NASDAQ Release: Bio-Path Holdings, Inc. to Ring The NASDAQ Stock Market Closing Bell (Friday, October 17, 2014 at 3:45 – 4:00 PM Eastern Time)

Bio-Path Holdings Successfully Completes Cohort 6 of Phase I Clinical Trial Evaluating Liposomal Grb-2 in Blood Cancers

Bio-Path Holdings to Present at the 13th Annual BIO Investor Forum in San Francisco on Tuesday October 7, 2014 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time)

Bio-Path Holdings Reports Second Quarter 2014 Operational and Financial Results

Bio-Path Holdings Added to Russell Global, Russell 3000 and Russell Microcap Indexes

Enrollment Continues Into Bio-Path Holdings Phase I Clinical Trial

Bio-Path Holdings Reports First Quarter 2014 Operational and Financial Results

Bio-Path Holdings Reports Fiscal Year 2013 Operational and Financial Results

Bio-Path Holdings, Inc. Appoints Ulrich M. Mueller Chief Operating Officer

Bio-Path Holdings Announces Uplisting to the NASDAQ Capital Market

Bio-Path Holdings, Inc. to Raise $10 Million in Registered Direct Offering

Bio-Path Holdings to Present at the Biotech Showcase 2014 Conference in San Francisco, CA on Wednesday, January 15, 2014 at 8:00 a.m. Pacific Time

Preliminary Results from Bio-Path Holdings’ Phase I Clinical Trial Presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans

Bio-Path Holdings Reports Third Quarter 2013 Operational and Financial Results

Data from Bio-Path Holdings Phase I Clinical Trial in Hematological Cancers to be Presented at American Society of Hematology Annual Meeting: Data Suggests Potential for AML and MDS Disease Inhibition with Liposomal Grb-2-

Bio-Path Holdings to Present at the 12th Annual BIO Investor Forum

Bio-Path Holdings, Inc. Retains Investment Banking Firm Maxim Group LLC

Bio-Path Holdings Reports Second Quarter 2013 Operational and Financial Results

Bio-Path Holdings’ Liposomal Delivery Technology Achieves Major Milestone in development of Antisense Therapeutics

Bio-Path Holdings Initiates Development of Liposomal Grb-2 for Triple Negative and Inflammatory Breast Cancers

Bio-Path Holdings Successfully Completes Fifty Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia

Bio-Path Holdings Reports First Quarter 2013 Operational and Financial Results

Bio-Path Holdings Reports Fiscal Year 2012 Operational and Financial Results

Bio-Path Holdings Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias

Bio-Path Holdings to Present at Biotech Showcase 2013 Conference in San Francisco, California on Tuesday, January 8, 2013 at 11:00 am Pacific Time

Bio-Path Holdings to Expand Development of Liposomal Grb-2 into two additional indications: Triple Negative and Inflammatory Breast Cancers

Bio-Path Holdings Reports Third Quarter 2012 Operational and Financial Results

Bio-Path Holdings Successfully Completes Fourth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia

Bio-Path Holdings Adds New Board Member

Bio-Path Holdings to Present at the 11th Annual Bio Investor Forum Conference in San Francisco on Wednesday Oct 10, 2012 at 11:30 am Pacific Time (2:30 pm Eastern Time)

Bio-Path Holdings to Present at the Rodman & Renshaw Annual Global Investment Conference

Bio-Path Holdings Reports Second Quarter 2012 Operational and Financial Results

Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias

Bio-Path Holdings Shares Commence Trading On OTCQX, The Top Tier Of The OTC Market

Bio-Path Holdings Successfully Completes Third Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia

Bio-Path Holdings Reports First Quarter 2012 Operational and Financial Results – Quarter Highlighted by Progress with Lead Product Candidate, Liposomal Grb-2

Bio-Path Holdings Reports Fiscal Year 2011 Operational and Financial Results

Bio-Path Holdings Engages PondelWilkinson for Retailer Investor Relations Program

Bio-Path Holdings Successfully Completes Second Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia

Bio-Path Holdings to Present at Biotech Showcase 2012 Conference

Bio-Path Holdings’ Initial Phase I Data in Leukemia Clinical Trial Demonstrates that Its Neutral Lipid Delivery Technology Antisense Drug BP-101-100-1.01 (Liposomal Grb-2) Is Well Tolerated with Activity Seen at Low-Starting Dose

Press Release Form 8-K – 3rd Quarter Financial Results

Proxy Statement fothereer 2011

Bio-Path Holdings to Present at the 10th Annual BIO Investors Forum Conference in San Francisco on Wednesday, October 26, 2011. Link to Conference at 3:00pm Pacific Time

Initial Data from Bio-Path Holdings’ Phase I Clinical Trial Accepted for Presentation at American Society ofHematology Annual Meeting

Bio-Path Holdings to Present at the Rodman & RenshawAnnual Global Investment Conference

First Cohort Successfully Completed in Bio-Path Holding’s Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia

Bio-Path recently featured in Genomeweb/Gene Silencing News

Bio-Path Holdings Reports First Quarter 2011 Financial Results

Bio-Path Holdings Appoints Dr. Ana M. Tari Director, Preclinical Operations and Research

Zack’s Small-Cap Research Release

Bio-Path Holdings Reports Fiscal Year 2010 Operation and Financial Results

Zack’s Small-Cap Research Release

CEOCFO Interviews Peter H. Nielsen, CEO

Bio-Path Holdings Reports Third Quarter 2010 Financial Results

Bio-Path Holdings Awarded Grant From The U.S. Government’s Qualifying Therapeutic Discovery Project Program

Bio-Path Holdings Reports Fiscal 2010 Second Quarter Financial Results Company Also Completes Initial Sale of Registered Shares Under Financing With Lincoln Park Capital

Bio-Path Holdings announces Dosing of First Patient in a Phase I Clinical Trial of its Liposomal Grb-2 Cancer Drug Candidate

Bio-Path Holdings Signs Equity Financing Deal Equity Purchase Agreement With Institutional Investor Lincoln Park Capital to Provide Up to $7 Million In New Capital

FDA Allows IND For Bio-Path Holdings’ Liposomal Grb-2 Company to Commence Phase I Clinical Trial Of Its Cancer Drug To Treat CML, AML, ALL, & MDS

Bio-Path Holdings, Inc. Completes Private Placement Capital Raise and Provides Update to IND Status

Bio-Path Holdings, Inc. Operations Update

Bio-Path Holdings, Inc. Announces Plans To Develop Liposome Tumor Targeting Technology Licensed from The University of Texas M. D. Anderson Cancer Center

Bio-Path Holdings, Inc. Provides Operations Update and Overview Of New Targeting Technology

Proxy

Proxy Statement

Bio-Path Holdings, Inc. Announces Clinical Support Agreement With ACORN And Names Bradley G. Somer, M.D., As Medical Officer For Phase I Clinical Trial

Letter To Shareholders

Bio-Path Holdings, Inc. Retains Alliance Advisors, LLC to Implement Investor Relations Program

Bio-Path Holdings, Inc. Announces the Signing of a Drug Manufacturing Agreement with Althea Technologies, Inc.

Bio-Path Becomes a Publicly Traded Company